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Abstract 1 
Although biomarkers are perceived as highly relevant for future clinical practice, few biomarkers 2 
reach clinical utility for several reasons. Among them, poor reporting of studies is one of the major 3 
problems. To aid improvement, reporting guidelines like REMARK for tumour marker prognostic 4 
(TMP) studies were introduced several years ago. The aims of this project were to assess whether 5 
reporting quality of TMP-studies improved in comparison to a previously conducted study assessing 6 
reporting quality of TMP-studies (PRE-study) and to assess whether articles citing REMARK (citing 7 
group) are better reported, in comparison to articles not citing REMARK (not-citing group).   8 
For the POST-study, recent articles citing and not citing REMARK (53 each) were identified in selected 9 
journals through systematic literature search and evaluated in same way as in the PRE-study. Ten of 10 
the 20 items of the REMARK checklist were evaluated and used to define an overall score of 11 
reporting quality.  12 
The observed overall scores were 53.4% (range: 10%-90%) for the PRE-study, 57.7% (range: 20%-13 
100%) for the not-citing group and 58.1% (range: 30%-100%) for the citing group of the POST-study. 14 
While there is no difference between the two groups of the POST-study, the POST-study shows a 15 
slight but not relevant improvement in reporting relative to the PRE-study. Not all the articles of the 16 
citing group, cited REMARK appropriately. Irrespective of whether REMARK was cited, the overall 17 
score was slightly higher for articles published in journals requesting adherence to REMARK than for 18 
those published in journals not requesting it:  59.9% versus 51.9%, respectively.  19 
Several years after the introduction of REMARK, many key items of TMP-studies are still very poorly 20 
reported. A combined effort is needed from authors, editors, reviewers and methodologists to 21 
improve the current situation. Good reporting is not just nice to have but is essential for any research 22 
to be useful.   23 
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Introduction                   1 
Major advances in molecular biology and in analytical laboratory methods including new (high-2 
throughput) technologies have enabled the detection and the measurement of a wide range of 3 
biomarkers in the human body. This has led to an increasing number of studies assessing the utility of 4 
biomarkers in a medical context [1, 2]. In this regard, a biomarker is an objectively measured 5 
characteristic with biological, clinical, genetic, histological or pathological background [3]. Biomarker 6 
measurement can be based on a single assessment or on a combination of information from several 7 
assessments (e.g. scores) [1, 4]. Biomarkers are already used successfully and routinely in different 8 
areas of medicine (e.g. serum creatinine to assess kidney function [5, 6]) and are perceived as highly 9 
relevant for future clinical practice using stratified or personalized medicine, where biomarkers may 10 
be useful to assist medical decision making, ideally underpinned by recommendations in clinical 11 
guidelines. Areas of biomarker use include but are not restricted to different aspects of patient care 12 
[2, 4, 7, 8]:  13 
• screening of people to allow early detection of diseases,  14 
• differential diagnosis of patients, 15 
• stratification of patients  for treatments, 16 
• monitoring of treatment response and treatment compliance, and 17 
• identification of risk groups related to patients’ prognosis. 18 
Biomarkers are also useful in the discovery and development of new treatments, through their role 19 
in elucidation of disease processes [4, 8]. Additionally, biomarkers are important in the design of 20 
studies and trials, allowing stratification of participants and use as surrogate endpoints [8, 9].  21 
There are several important steps to establish the clinical value of a particular biomarker, 22 
including well-designed and well-reported clinical studies [1, 9-11]. Yet very few biomarkers have 23 
established clinical value [1, 12, 13], as exemplified by cancer research where it is estimated that 24 
fewer than 1% of biomarkers originally proposed as important have entered clinical practice [14]. 25 
Researchers have investigated reasons for this unsatisfactory situation. Different types of failures 26 
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were distinguished, especially where results of subsequent studies contradict preceding study results 1 
[14-16]. There are major concerns that the poor quality of studies can lead to misleading results and 2 
consequently mistaken claims of utility [1, 3, 12, 17, 18].   3 
As biomarker studies can be challenging, methodologists have highlighted the need for more 4 
transparency, standardization and harmonization to improve studies [11, 13, 19-23]. Overall, this will 5 
not only help to improve quality of individual studies but also enhance the ability to compare results 6 
between studies – a prerequisite for evidence synthesis and meta-analysis. A typical example is 7 
provided by p53. Since the early 1990s, p53 has been measured by immunohistochemistry and 8 
assessed as a potential prognostic biomarker in bladder cancer in many studies. Although 9 
researchers invested a lot of effort, time and money, the research question is still unanswered [24-10 
28]. This situation is a consequence of many different methodological issues, such as small study 11 
populations and variation in study methods resulting in differences in the handling of measurements 12 
(e.g. different cutpoints used to define positive biomarker results).  13 
Poor reporting is another major problem in these studies. Many biomarker studies are never 14 
reported at all and there is evidence that publication is linked to study results; Kyzas et al found that 15 
<1.5% of published prognostic marker studies were found to have only “negative” results [29]. 16 
Within published studies, there are problems with the selective reporting of results and with the 17 
poor quality of reporting of methods and results [3, 21]. For tumour marker prognostic studies (TMP-18 
studies), evidence for bad reporting has been provided [30]. In general, publications that are of poor 19 
quality can be essentially considered as a waste of research resources [31]. Worse, poor reporting in 20 
published studies might lead to incorrect conclusions about the evidence relating to a specific 21 
question. 22 
To help overcome issues regarding the poor quality of reporting, guidelines for specific 23 
research areas were introduced. A valuable research hub is provided by the EQUATOR Network 24 
providing searchable access to reporting guidelines appropriate for many study designs and specific 25 
study features [32]. Among others, the REMARK guideline (short: REMARK) is a reporting guideline 26 
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specifically for TMP-studies assessing biomarkers in relation to future health outcomes in cancer 1 
patients. This guideline was published in seven journals in 2005/6 [33-39]. For convenience, the 2 
authors provided a checklist of 20 items addressing different parts of a manuscript. REMARK can be 3 
used by authors, editors and reviewers to check the reporting quality of a study report (S1 Doc). In 4 
addition, an extensive ‘Explanation and Elaboration’ (E&E) article was published in 2012, providing 5 
detailed information and examples of good reporting practice for each of these checklist items [40, 6 
41]. The need for REMARK was supported by a study that strikingly showed the poor reporting 7 
quality of 50 TMP-studies published in 2006-7 [30]. Because of the usual delay before an article is 8 
published, it is most unlikely that the authors of the assessed articles knew REMARK at the time of 9 
writing their manuscript (pre-REMARK period). 10 
The aim of this project was to evaluate whether the quality of reporting of such studies has 11 
improved since the publication of REMARK (post-REMARK period). We repeated the previous study 12 
(short: PRE-study) using articles published between 2007 to 2012 (short: POST-study) using methods 13 
and definitions as similar as possible, to allow a fair comparison with previous findings [30]. Some 14 
TMP-studies cite the REMARK guidelines demonstrating awareness of REMARK, sometimes because 15 
journals like Breast Cancer Research and Treatment (BCRT) ask for adherence to REMARK in 16 
submitted manuscripts [42]. In contrast, authors of articles not citing the guideline are more likely to 17 
be unaware of REMARK or may not be using the checklist. In this study, we also addressed the 18 
question whether citing the REMARK guideline or not is related to the reporting quality. In summary, 19 
the two aims of the project are: 20 
1. Has there been any improvement in reporting quality since introduction of REMARK? 21 
2. Is reporting better in studies citing REMARK? 22 
 23 
  24 
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Material and Methods 1 
Because only published data from studies in humans were utilized, no approval from an ethic 2 
committee was obtained. 3 
To allow a direct comparison to the previous work [30], the POST-study was designed in a 4 
very similar way (choice of journals, study selection, data extraction). In this study, two groups of 5 
publications were distinguished: (A) publications that cited one of the seven REMARK publications 6 
(citing group) and (B) publications that did not cite REMARK (not-citing group) [33-39]. Similarly to 7 
the PRE-study, it was planned to include 50 articles per group as sufficient size in this methodological 8 
study to address questions of interest. 9 
 10 
1 Literature search 11 
To identify TMP-studies citing REMARK, a literature search was done in Web of Science in March 12 
2013. References of all publications citing at least one of the REMARK publications were extracted 13 
and imported into Endnote [33-39]. After removal of duplicates (n=72), 998 articles published in 278 14 
different journals were identified. Among them, 134 publications were in one of the five previously 15 
considered cancer journals: Cancer [Canc], Cancer Research [CaRes], International Journal of Cancer 16 
[IJC], Journal of Clinical Oncology [JCO], Clinical Cancer Research [CCR].   17 
 The 134 identified articles published in the five journals considered in the PRE-study were 18 
then examined to identify for each journal the 10 most recent TMP-studies that cited REMARK. A 19 
detailed description of the eligibility criteria can be found in the S2 Doc. Essentially, studies assessing 20 
the prognostic impact of a specific biomarker on an outcome of clinical importance (e.g. cancer-21 
specific survival) in cancer patients were eligible. The search revealed 10 articles each from JCO and 22 
CCR, 7 from IJC, 6 from Canc and 1 from CaRes. Because of this result, we decided to exclude CaRes 23 
from further consideration and to include two further cancer journals (Breast Cancer Research and 24 
Treatment [BCRT] and British Journal of Cancer [BJC]) for which 10 articles each could be identified. 25 
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Altogether, the citing group comprised 53 articles. Although about 80% of the included manuscripts 1 
were published in 2011 and 2012, a few dated back to 2007. 2 
To identify publications not citing REMARK, we aimed to obtain for each article citing 3 
REMARK another article from the same journal that did not, closely matched in time (publication 4 
year and, if possible, issue). The same number of articles (n=53) was identified forming the not-citing 5 
group.  6 
The described search is depicted in Fig 1. The references of all selected articles are listed in 7 
S3 Doc. 8 
 9 
Fig 1: Literature search – flow chart 10 
 11 
2 Data extraction 12 
For all 106 articles from the six journals we obtained the full text. For data extraction, we used the 13 
same standardized form that had been used in the PRE-study (S4 Doc) [30]. This form lists several 14 
elements (specific questions) addressing different items of the REMARK checklist. The focus of data 15 
extraction led on information related to methods and results of a study. Because of the general 16 
character of each checklist item, a specific item is often described by more than 1 element of the 17 
data extraction form.  18 
To ensure good comparability of extracted data with past results, a pilot data extraction for 19 
eight articles was done in duplicate by the author (SM) who mainly did the data extraction in the 20 
PRE-study and another author (PS) who was responsible for it in the POST-study. Results of these 21 
extractions were compared and differences clarified before data extractions were done for the 22 
remaining articles by PS alone. 23 
For articles in which several biomarkers were assessed in a study in parallel, the biomarker 24 
first mentioned in title or abstract for which a multivariable analysis was done was defined to be the 25 
focus of the data extraction. A similar approach was used when different study populations were 26 
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assessed within a single article. Two groups of time-to-event outcomes were distinguished: death-1 
related outcomes (overall survival, cancer-specific survival) and other time-to-event outcomes 2 
(disease-free survival, time until recurrence/relapse). Similarly, when several outcomes were 3 
assessed in a study the data extraction focused on the outcome that was first mentioned in title or 4 
abstract for which a multivariable analysis had been conducted.       5 
Importantly, this project focuses only on the assessment of reporting quality and not on the 6 
general appropriateness of methods, including study design, assessed biomarkers, statistical 7 
methods and outcomes considered.      8 
 9 
3 Analyses 10 
We addressed our first aim on the improvement over time by comparing the results obtained in the 11 
PRE-study to those of the not-citing group. The second aim on difference in reporting when citing or 12 
not citing REMARK was addressed by comparing the results for the citing and not-citing groups within 13 
the current POST-study.  14 
The intended comparisons were descriptively conducted with respect to 10 of the 20 items of 15 
the REMARK checklist that are related to methods and results of a manuscript (Table 1). For each 16 
article, we evaluated whether information for each item was provided (yes/no) by combining 17 
extracted information of elements assigned to that item. Details regarding selection of checklist 18 
items and definitions how items were evaluated are provided in S5 Doc. Finally, for each article an 19 
overall score was obtained as the percentage of items addressed out of 10.  20 
 21 
  22 
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Table 1: Overview of the 10 assessed items of the REMARK checklist 1 
No. Manuscript 
part 
Item of REMARK 
checklist 
Short description Abbreviation used 
in article 
1 Methods 2 PATient characteristics PAT 
2 6 Study DESign: patient selection & time period DES 
3 7 Clinical ENDpoints END 
4 9 Rationale for sample SIZe SIZ 
5 10 All statistical METhods MET 
6 Results 12 FLOw of patients FLO 
7 13 Distribution of DEMographic characteristics DEM 
8 14 RELationship between marker and standard variables REL 
9 15 UNIvariate analyses UNI 
10 16 MULtivariable analyses MUL 
 2 
Only 10 checklist items were included in the assessment of adherence to REMARK as we used 3 
only items we could assess objectively and that could be assessed on TMP-studies from any research 4 
area. Items 1, 19 and 20 referring to the introduction and the discussion of an article were 5 
considered too subjective and require subject-specific expert knowledge, and so had not been 6 
included in the data extraction form that was already used in the PRE-study. Similarly, the seven 7 
items 3, 4, 5, 8, 11, 17 and 18 referring to the methods and the results of an article were excluded 8 
because their evaluation essentially requires profound expert knowledge with respect to the medical 9 
background and methodology. For more details, see S5 Doc. 10 
 11 
  12 
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4 Reporting 1 
This study assesses the reporting quality of published TMP-studies. For such a ‘research on research’-2 
project, no specific reporting guideline is available. The current project, however, shows some 3 
features (observational kind, literature search) that allow us to use different reporting statements as 4 
guidance. Specifically, we used the STROBE guideline for general aspects of the project and the 5 
PRISMA statement for aspects around literature search [43, 44].  6 
 7 
  8 
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Results 1 
 2 
1 Selected journals and assessed articles 3 
Overall 4 
The POST-study was planned to use the same journals as much as was feasible, but some changes to 5 
journals was required for practical reasons (Table 2). All journals are of higher impact (impact factor 6 
2012 >4). Three journals (BCRT, BJC, JCO) belong to the group of journals that have published 7 
REMARK. These three journals and CCR explicitly ask authors submitting a manuscript for adherence 8 
to REMARK (Table 2). 9 
 10 
Table 2: Cancer journals included in the PRE-study and in the POST-study 11 
Journal 
(alphabetical 
order) 
PRE-study POST-study Impact 
factor† 
2012 
Publication 
of REMARK 
Author instructed 
to adhere to 
REMARK 
 N assessed 
articles 
 N assessed 
articles* 
02/2009‡ 08/2014 
BCRT - -  10/10 4.5 YES [38] YES [42] YES 
BJC - -  10/10 5.1 YES [33] UNK YES 
Canc  10  6/6 5.2 NO NO NO 
CaRes  10 - -§ 8.6 NO NO NO 
CCR  10  10/10 7.8 NO YES YES 
IJC  10  7/7 6.2 NO NO NO 
JCO  10  10/10 18.0 YES [35] YES YES 
* N citing group/n not-citing group; † source: InCitesTM Journal Citation Reports; ‡ check was done within the PRE-study; §journal was 12 
excluded because only one eligible article citing REMARK was identified; UNK=unknown 13 
  14 
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The sample included 53 articles in both the citing group and the not-citing group (total 1 
n=106). Similarly to the PRE-study, the distribution of cancer sites was diverse. As a consequence of 2 
the additional inclusion of BCRT, however, the proportion of breast and/or ovarian cancer studies 3 
was higher in the current sample (PRE-study: 30%, POST-study: 44%). Articles in the not-citing and 4 
citing groups were well matched by journal, year and issue (S1 Table). 5 
 6 
Citing group 7 
At least one of the REMARK publications was referenced in all the articles assigned to the citing 8 
group.  Since REMARK is a methodological tool, its citation is expected to be given in the methods 9 
section of the article, with a statement like “The study is reported in accordance to the REMARK 10 
guideline”. Although REMARK was indeed cited most often in the methods section (n=39, 74%), some 11 
citations appeared in other sections of the manuscripts. The statements in which REMARK was cited 12 
varied greatly. While some authors correctly referred to the reporting of the study, other authors 13 
referred to REMARK in relation to the design, the conduct and the analysis of the study. For example, 14 
the statement “This analysis was conducted according to the reporting recommendations for tumor 15 
marker guidelines for prognostic studies …” was provided by the authors in the methods section [45]. 16 
Other statements are difficult to understand, such as “Protein expression was evaluated using a 17 
semiquantitative weighted histoscore method by two observers as previously described … in 18 
accordance with the Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) 19 
guidelines …” [46]. 20 
Three manuscripts were accompanied by a completed REMARK checklist [47-49]; two of 21 
these had overlapping authorship [47, 48]. For unknown reasons, none of these lists cover the full 22 
REMARK checklist of 20 items. Moreover, some explanations were difficult to assess, for example 23 
regarding the item ‘Flow of patients’, the authors stated “This is not a staged analysis. The evaluated 24 
cohort is described …” [48]. 25 
 26 
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2 Comparison of reporting quality 1 
Not-citing group (POST-study) versus PRE-study 2 
Overall, there was a slight but not relevant improvement in the mean overall score: PRE-study 53.4% 3 
(range: 10%-90%), not-citing group of POST-study 57.7% (range: 20%-100%, Wilcoxon rank sum test: 4 
p = 0.33, Fig 2). This small difference, however, vanished when we included only articles published in 5 
the four journals assessed in both periods: PRE-study 56.5% (range: 10%-80%, n=40), not-citing group 6 
of POST-study 56.4% (range: 20%-80%, n=33). Some items showed an improvement in reporting from 7 
the past to the present, while others showed a decline (S2 Table). An improvement, for example, was 8 
visible for item 2 ‘Patient characteristics’ (PAT): PRE-study 54%, POST-study 72%. In this case, the 9 
improvement was also visible for the single assigned elements like the element ‘Selection of patients’ 10 
(PAT1) showing improvement from 64% in the PRE-study to 77% in the not-citing group (Fig 3A). In 11 
contrast, a remarkable decline from past to present was seen for item 9 ‘Rationale for sample size’ 12 
(SIZ; Fig 3B, S5 Doc). Overall, there remains much room for improvement of reporting. 13 
 14 
Fig 2: Percentages of articles adequately reporting information for 10 selected items of the 15 
REMARK checklist.  16 
The items are sorted by percentages obtained in the PRE-study [30]. See Table 1 or S2 Table for 17 
explanation of abbreviations used for different checklist items. 18 
 19 
Fig 3: Percentages of articles adequately reporting information for two checklist items and their 20 
single elements respectively assigned.  21 
(A) Checklist item 2 ‘Patient characteristics’ (PAT), (B) checklist item 9 ‘Rationale for sample size’ 22 
(SIZ). See S2 Table for explanation of abbreviations used for different elements of data extraction and 23 
checklist items. 24 
  25 
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Citing group versus not-citing group (POST-study) 1 
When comparing the not-citing group and the citing group, there was essentially no difference in 2 
mean scores: not-citing group 57.7% (range: 20%-100%), citing group 58.1% (range: 30%-100%, Fig 3 
2). Again, some single checklist items showed an improvement in reporting from the past to the 4 
present, while others showed a decline. Most pronounced, item 7 ‘Clinical endpoints’ (END)  was 5 
reported better in the citing group than in the non-citing group (40% vs 66%, respectively; S2 Table), 6 
whereas it was the other way around for item 13 ‘Distribution of demographic characteristics’ (DEM; 7 
55% vs 42%). Fig 3 similarly illustrates observed percentages for item 2 (PAT) and item 9 (SIZ). 8 
 9 
Additional analysis 10 
Because we observed some unexpected statements by authors citing REMARK which could imply a 11 
lack of understanding of REMARK as a reporting guideline, an additional comparison was made of 12 
articles grouped by journals requesting (4 journals, 80 articles) or not requesting (2 journals, 26 13 
articles) adherence to REMARK, irrespective whether authors cited or not cited REMARK (Table 2). 14 
On average, the overall score for articles published in journals requesting adherence to REMARK was 15 
higher (59.9%) than for the other group (51.9%). This ordering was also present for each single 16 
checklist item. 17 
 18 
  19 
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Discussion 1 
Several years after REMARK was introduced, and with many published discussions of the reporting 2 
quality in health research and prominence given to the role of poor reporting in contributing to 3 
research waste, some improvement of the reporting quality of TMP-studies was expected [30, 50, 4 
51]. However, our assessment of articles from the post-REMARK period did not reveal any relevant 5 
improvement over the quality of articles assessed in the earlier study [30]. The overall reporting 6 
quality is still very poor. Authors still frequently fail to report important aspects of their study such as 7 
the source of the study population, fully defined clinical endpoints, and an explanation of the sample 8 
size. 9 
Moreover, we observed essentially no difference in reporting quality when comparing 10 
articles citing and not citing REMARK. Because citing REMARK means the author of the respective 11 
article is aware of the guideline, one would expect to see superior reporting quality compared to 12 
articles not citing REMARK.  Our findings, however, raise the question of whether the main scope of 13 
REMARK is really understood. To overcome any misunderstanding the REMARK group already 14 
published a manuscript that elaborates and explains each item of the REMARK checklist in detail [40, 15 
41]. However, authors of articles assessed in this project (published ≤2012) could not have known 16 
this amendment because it was published in 2012. 17 
Because of these disappointing results we decided to conduct an additional unplanned 18 
comparison between reporting qualities of articles published in journals requesting or not requesting 19 
adherence to REMARK in the submission guidelines. This revealed somewhat better reporting in the 20 
group of articles published in journals requesting adherence to REMARK.  21 
 22 
  23 
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1 Limitations of study 1 
To allow a fair comparison of results between past and current assessments, the current project was 2 
designed to be as similar as possible to the previous study. Also, the current team largely overlaps 3 
with the team of the past study. Furthermore, all the documents including the data extraction form 4 
could be utilized. A pilot study was conducted to ensure comparability between data extractions in 5 
the past and current projects. Still, some systematic differences between the two surveys cannot be 6 
ruled out. In addition although judged as sufficient to address the methodological research question, 7 
the number of studies assessed was relatively small in both the pre-study and the current study. 8 
 One obvious limitation of this study is that we could not identify enough articles in all 9 
journals considered in the first study, so two new journals (BCRT, BJC) were included. Since both 10 
additional journals published REMARK and requesting adherence to it, the overall result might be 11 
biased. For this reason, an additional analysis was conducted by restricting articles to those published 12 
in the four journals Canc, CCR, IJC and JCO that were considered in both assessments. As result, the 13 
small improvement observed in the overall sample vanished. Overall we found no improvement in 14 
reporting quality of prognostic factor studies in the first (about six) years since REMARK was 15 
published.  Repeating the investigation with papers published after more than ten years (say in 2016) 16 
may provide better results.   17 
 Another issue relates to the overall score used to evaluate quality of reporting. The overall 18 
score included summation of sufficiently reported REMARK items, often based on several elements 19 
of the data extraction form. For transparency, a description of the overall score and detailed results 20 
are provided in the supporting information (S5 Doc, S2 Table). 21 
 22 
  23 
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2 Our findings in the context of published literature 1 
To our knowledge, there is just one other published study assessing quality of TMP-studies, which 2 
reviews studies of prognostic markers for colorectal cancer published in 2009-11, a slightly earlier  3 
period to the current project [52]. The authors assessed adherence to the complete REMARK 4 
checklist and found a mean score of 60 out of 78, but still emphasize deficiencies in reporting similar 5 
to those seen in our study across all cancers.  6 
 Concern about reporting quality applies across all areas of health research. To overcome this 7 
problem reporting guidelines for many different study designs and research areas are available [32]. 8 
Similarly to our project, other study groups also assessed the question of whether reporting quality 9 
improved over time. For randomized controlled trials and in relation to the CONSORT statement, 10 
modest improvement in reporting quality was reported but reporting was still considered suboptimal 11 
[53, 54]. For other guidelines like STARD or STROBE, some slight improvements were also reported 12 
[55-58]. The current study on REMARK is essentially in line with those other reported results.  13 
Da Costa et al systematically examined reasons for citing STROBE guideline [43, 59]. Similar 14 
to our observations, the authors reported that the guideline is often used inappropriately. These 15 
observations raise doubts on the general understanding of reporting guidelines and their aim, as 16 
already discussed in 2008 [60].        17 
 Evidence of a relation between reporting quality and endorsement of reporting guidelines by 18 
journals is limited [54, 61]. Our data suggest that a request of adherence by the journal might be 19 
useful. In order to provide conclusive evidence, well-planned prospective studies in cooperation with 20 
editors are needed to explore and enhance journal editor led interventions to improve reporting 21 
[61].  22 
Based on our experience in the current project, we became aware that expert knowledge of 23 
the research subject and methods is often required to evaluate details needed for good reporting. 24 
Editors and reviewers may find it hard to recruit and focus experts on reporting as well as results of 25 
research studies. For authors writing a manuscript, access to sufficient expertise should be easier 26 
18 
 
because the research team should include experts relevant to the clinical and methodological aspects 1 
of a study. On the other hand, reporting guidelines are misunderstood by many authors [62], and 2 
further initiatives like the E&E paper for REMARK may be very helpful [40, 41].   3 
 4 
3 Quality of medical research in general 5 
In general, the quality of medical research, including other aspects besides reporting, has been 6 
criticized heavily in the last years [1, 14, 19, 31, 63-66].  To overcome these issues, several important 7 
contributions as well as the introduction of reporting guidelines have been seen recently. For 8 
example, the PROGnosis RESearch Strategy (PROGRESS) group published a series of articles to 9 
provide a framework on different aspects in prognostic research [11, 67-70]. Also, the STRATOS 10 
(STRengthening Analytical Thinking for Observational Studies) initiative was founded recently that 11 
aims to derive guidance documents related to design and analysis of observational studies [71, 72].  12 
Overall, the need for transparency in medical research still appears to lack widespread 13 
acceptance and research endeavour [21, 23, 73]. Researchers remain insufficiently aware of the need 14 
to make their research clear and understandable to other researchers, as well as practising 15 
physicians, patients and other stakeholders (e.g. pharmaceutical companies, funding agencies). 16 
Particularly in medical research it is important that studies can be repeated by other research groups, 17 
requiring transparency through good reporting of research methods and results. 18 
Registration of all studies and data sharing [1, 23, 73-76] have been recommended to 19 
improve knowledge of ongoing and past research. In this context, good reporting is a main 20 
prerequisite. Even a well-conducted and well-analysed study that is poorly reported can be 21 
considered as waste of resources.  22 
 23 
  24 
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Conclusions  1 
Tumour marker prognostic studies are still very poorly reported. To improve the situation the 2 
REMARK recommendations need to be followed. However, this study is another example illustrating 3 
that publication of guidelines is insufficient and that more pressure on authors, reviewers and editors 4 
is needed to improve on this unfortunate situation. We support the proposal of one reviewer of this 5 
manuscript that an electronic checklist (a web-based form of the checklist on which the authors can 6 
indicate where in the manuscript information for an item is addressed) can be a valuable instrument 7 
of the submission process. Ideally, such an electronic document can also provide further information 8 
about the reporting items. We hope that more journals will be willing to request such checklists in 9 
their submission process. Good reporting is not just nice to have. It is essential for any research to be 10 
useful but also for the limitations of research to be understood. Good reporting is also essential for 11 
systematic reviews that bring together and overview research studies to achieve a high level of 12 
evidence.   13 
20 
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Abstract 1 
Although biomarkers are perceived as highly relevant for future clinical practice, few biomarkers 2 
reach clinical utility for several reasons. Among them, poor reporting of studies is one of the major 3 
problems. To aid improvement, reporting guidelines like REMARK for tumour marker prognostic 4 
(TMP) studies were introduced several years ago. The aims of this project were to assess whether 5 
reporting quality of TMP-studies improved in comparison to a previously conducted study assessing 6 
reporting quality of TMP-studies (PRE-study) and to assess whether articles citing REMARK (citing 7 
group) are better reported, in comparison to articles not citing REMARK (not-citing group).   8 
For the POST-study, recent articles citing and not citing REMARK (53 each) were identified in selected 9 
journals through systematic literature search and evaluated in same way as in the PRE-study. Ten of 10 
the 20 items of the REMARK checklist were evaluated and used to define an overall score of 11 
reporting quality.  12 
The observed overall scores were 53.4% (range: 10%-90%) for the PRE-study, 57.7% (range: 20%-13 
100%) for the not-citing group and 58.1% (range: 30%-100%) for the citing group of the POST-study. 14 
While there is no difference between the two groups of the POST-study, the POST-study shows a 15 
slight but not relevant improvement in reporting relative to the PRE-study. Not all the articles of the 16 
citing group, cited REMARK appropriately. Irrespective of whether REMARK was cited, the overall 17 
score was slightly higher for articles published in journals requesting adherence to REMARK than for 18 
those published in journals not requesting it:  59.9% versus 51.9%, respectively.  19 
Several years after the introduction of REMARK, many key items of TMP-studies are still very poorly 20 
reported. A combined effort is needed from authors, editors, reviewers and methodologists to 21 
improve the current situation. Good reporting is not just nice to have but is essential for any research 22 
to be useful.   23 
3 
 
Introduction                   1 
Major advances in molecular biology and in analytical laboratory methods including new (high-2 
throughput) technologies have enabled the detection and the measurement of a wide range of 3 
biomarkers in the human body. This has led to an increasing number of studies assessing the utility of 4 
biomarkers in a medical context [1, 2]. In this regard, a biomarker is an objectively measured 5 
characteristic with biological, clinical, genetic, histological or pathological background [3]. Biomarker 6 
measurement can be based on a single assessment or on a combination of information from several 7 
assessments (e.g. scores) [1, 4]. Biomarkers are already used successfully and routinely in different 8 
areas of medicine (e.g. serum creatinine to assess kidney function [5, 6]) and are perceived as highly 9 
relevant for future clinical practice using stratified or personalized medicine, where biomarkers may 10 
be useful to assist medical decision making, ideally underpinned by recommendations in clinical 11 
guidelines. Areas of biomarker use include but are not restricted to different aspects of patient care 12 
[2, 4, 7, 8]:  13 
• screening of people to allow early detection of diseases,  14 
• differential diagnosis of patients, 15 
• stratification of patients  for treatments, 16 
• monitoring of treatment response and treatment compliance, and 17 
• identification of risk groups related to patients’ prognosis. 18 
Biomarkers are also useful in the discovery and development of new treatments, through their role 19 
in elucidation of disease processes [4, 8]. Additionally, biomarkers are important in the design of 20 
studies and trials, allowing stratification of participants and use as surrogate endpoints [8, 9].  21 
There are several important steps to establish the clinical value of a particular biomarker, 22 
including well-designed and well-reported clinical studies [1, 9-11]. Yet very few biomarkers have 23 
established clinical value [1, 12, 13], as exemplified by cancer research where it is estimated that 24 
fewer than 1% of biomarkers originally proposed as important have entered clinical practice [14]. 25 
Researchers have investigated reasons for this unsatisfactory situation. Different types of failures 26 
4 
 
were distinguished, especially where results of subsequent studies contradict preceding study results 1 
[14-16]. There are major concerns that the poor quality of studies can lead to misleading results and 2 
consequently mistaken claims of utility [1, 3, 12, 17, 18].   3 
As biomarker studies can be challenging, methodologists have highlighted the need for more 4 
transparency, standardization and harmonization to improve studies [11, 13, 19-23]. Overall, this will 5 
not only help to improve quality of individual studies but also enhance the ability to compare results 6 
between studies – a prerequisite for evidence synthesis and meta-analysis. A typical example is 7 
provided by p53. Since the early 1990s, p53 has been measured by immunohistochemistry and 8 
assessed as a potential prognostic biomarker in bladder cancer in many studies. Although 9 
researchers invested a lot of effort, time and money, the research question is still unanswered [24-10 
28]. This situation is a consequence of many different methodological issues, such as small study 11 
populations and variation in study methods resulting in differences in the handling of measurements 12 
(e.g. different cutpoints used to define positive biomarker results).  13 
Poor reporting is another major problem in these studies. Many biomarker studies are never 14 
reported at all and there is evidence that publication is linked to study results; Kyzas et al found that 15 
<1.5% of published prognostic marker studies were found to have only “negative” results [29]. 16 
Within published studies, there are problems with the selective reporting of results and with the 17 
poor quality of reporting of methods and results [3, 21]. For tumour marker prognostic studies (TMP-18 
studies), evidence for bad reporting has been provided [30]. In general, publications that are of poor 19 
quality can be essentially considered as a waste of research resources [31]. Worse, poor reporting in 20 
published studies might lead to incorrect conclusions about the evidence relating to a specific 21 
question. 22 
To help overcome issues regarding the poor quality of reporting, guidelines for specific 23 
research areas were introduced. A valuable research hub is provided by the EQUATOR Network 24 
providing searchable access to reporting guidelines appropriate for many study designs and specific 25 
study features [32]. Among others, the REMARK guideline (short: REMARK) is a reporting guideline 26 
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specifically for TMP-studies assessing biomarkers in relation to future health outcomes in cancer 1 
patients. This guideline was published in seven journals in 2005/6 [33-39]. For convenience, the 2 
authors provided a checklist of 20 items addressing different parts of a manuscript. REMARK can be 3 
used by authors, editors and reviewers to check the reporting quality of a study report (S1 Doc). In 4 
addition, an extensive ‘Explanation and Elaboration’ (E&E) article was published in 2012, providing 5 
detailed information and examples of good reporting practice for each of these checklist items [40, 6 
41]. The need for REMARK was supported by a study that strikingly showed the poor reporting 7 
quality of 50 TMP-studies published in 2006-7 [30]. Because of the usual delay before an article is 8 
published, it is most unlikely that the authors of the assessed articles knew REMARK at the time of 9 
writing their manuscript (pre-REMARK period). 10 
The aim of this project was to evaluate whether the quality of reporting of such studies has 11 
improved since the publication of REMARK (post-REMARK period). We repeated the previous study 12 
(short: PRE-study) using articles published between 2007 to 2012 (short: POST-study) using methods 13 
and definitions as similar as possible, to allow a fair comparison with previous findings [30]. Some 14 
TMP-studies cite the REMARK guidelines demonstrating awareness of REMARK, sometimes because 15 
journals like Breast Cancer Research and Treatment (BCRT) ask for adherence to REMARK in 16 
submitted manuscripts [42]. In contrast, authors of articles not citing the guideline are more likely to 17 
be unaware of REMARK or may not be using the checklist. In this study, we also addressed the 18 
question whether citing the REMARK guideline or not is related to the reporting quality. In summary, 19 
the two aims of the project are: 20 
1. Has there been any improvement in reporting quality since introduction of REMARK? 21 
2. Is reporting better in studies citing REMARK? 22 
 23 
  24 
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Material and Methods 1 
Because only published data from studies in humans were utilized, no approval from an ethic 2 
committee was obtained. 3 
To allow a direct comparison to the previous work [30], the POST-study was designed in a 4 
very similar way (choice of journals, study selection, data extraction). In this study, two groups of 5 
publications were distinguished: (A) publications that cited one of the seven REMARK publications 6 
(citing group) and (B) publications that did not cite REMARK (not-citing group) [33-39]. Similarly to 7 
the PRE-study, it was planned to include 50 articles per group as sufficient size in this methodological 8 
study to address questions of interest. 9 
 10 
1 Literature search 11 
To identify TMP-studies citing REMARK, a literature search was done in Web of Science in March 12 
2013. References of all publications citing at least one of the REMARK publications were extracted 13 
and imported into Endnote [33-39]. After removal of duplicates (n=72), 998 articles published in 278 14 
different journals were identified. Among them, 134 publications were in one of the five previously 15 
considered cancer journals: Cancer [Canc], Cancer Research [CaRes], International Journal of Cancer 16 
[IJC], Journal of Clinical Oncology [JCO], Clinical Cancer Research [CCR].   17 
 The 134 identified articles published in the five journals considered in the PRE-study were 18 
then examined to identify for each journal the 10 most recent TMP-studies that cited REMARK. A 19 
detailed description of the eligibility criteria can be found in the S2 Doc. Essentially, studies assessing 20 
the prognostic impact of a specific biomarker on an outcome of clinical importance (e.g. cancer-21 
specific survival) in cancer patients were eligible. The search revealed 10 articles each from JCO and 22 
CCR, 7 from IJC, 6 from Canc and 1 from CaRes. Because of this result, we decided to exclude CaRes 23 
from further consideration and to include two further cancer journals (Breast Cancer Research and 24 
Treatment [BCRT] and British Journal of Cancer [BJC]) for which 10 articles each could be identified. 25 
7 
 
Altogether, the citing group comprised 53 articles. Although about 80% of the included manuscripts 1 
were published in 2011 and 2012, a few dated back to 2007. 2 
To identify publications not citing REMARK, we aimed to obtain for each article citing 3 
REMARK another article from the same journal that did not, closely matched in time (publication 4 
year and, if possible, issue). The same number of articles (n=53) was identified forming the not-citing 5 
group.  6 
The described search is depicted in Fig 1. The references of all selected articles are listed in 7 
S3 Doc. 8 
 9 
Fig 1: Literature search – flow chart 10 
 11 
2 Data extraction 12 
For all 106 articles from the six journals we obtained the full text. For data extraction, we used the 13 
same standardized form that had been used in the PRE-study (S4 Doc) [30]. This form lists several 14 
elements (specific questions) addressing different items of the REMARK checklist. The focus of data 15 
extraction led on information related to methods and results of a study. Because of the general 16 
character of each checklist item, a specific item is often described by more than 1 element of the 17 
data extraction form.  18 
To ensure good comparability of extracted data with past results, a pilot data extraction for 19 
eight articles was done in duplicate by the author (SM) who mainly did the data extraction in the 20 
PRE-study and another author (PS) who was responsible for it in the POST-study. Results of these 21 
extractions were compared and differences clarified before data extractions were done for the 22 
remaining articles by PS alone. 23 
For articles in which several biomarkers were assessed in a study in parallel, the biomarker 24 
first mentioned in title or abstract for which a multivariable analysis was done was defined to be the 25 
focus of the data extraction. A similar approach was used when different study populations were 26 
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assessed within a single article. Two groups of time-to-event outcomes were distinguished: death-1 
related outcomes (overall survival, cancer-specific survival) and other time-to-event outcomes 2 
(disease-free survival, time until recurrence/relapse). Similarly, when several outcomes were 3 
assessed in a study the data extraction focused on the outcome that was first mentioned in title or 4 
abstract for which a multivariable analysis had been conducted.       5 
Importantly, this project focuses only on the assessment of reporting quality and not on the 6 
general appropriateness of methods, including study design, assessed biomarkers, statistical 7 
methods and outcomes considered.      8 
 9 
3 Analyses 10 
We addressed our first aim on the improvement over time by comparing the results obtained in the 11 
PRE-study to those of the not-citing group. The second aim on difference in reporting when citing or 12 
not citing REMARK was addressed by comparing the results for the citing and not-citing groups within 13 
the current POST-study.  14 
The intended comparisons were descriptively conducted with respect to 10 of the 20 items of 15 
the REMARK checklist that are related to methods and results of a manuscript (Table 1). For each 16 
article, we evaluated whether information for each item was provided (yes/no) by combining 17 
extracted information of elements assigned to that item. Details regarding selection of checklist 18 
items and definitions how items were evaluated are provided in S5 Doc. Finally, for each article an 19 
overall score was obtained as the percentage of items addressed out of 10.  20 
 21 
  22 
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Table 1: Overview of the 10 assessed items of the REMARK checklist 1 
No. Manuscript 
part 
Item of REMARK 
checklist 
Short description Abbreviation used 
in article 
1 Methods 2 PATient characteristics PAT 
2 6 Study DESign: patient selection & time period DES 
3 7 Clinical ENDpoints END 
4 9 Rationale for sample SIZe SIZ 
5 10 All statistical METhods MET 
6 Results 12 FLOw of patients FLO 
7 13 Distribution of DEMographic characteristics DEM 
8 14 RELationship between marker and standard variables REL 
9 15 UNIvariate analyses UNI 
10 16 MULtivariable analyses MUL 
 2 
Only 10 checklist items were included in the assessment of adherence to REMARK as we used 3 
only items we could assess objectively and that could be assessed on TMP-studies from any research 4 
area. Items 1, 19 and 20 referring to the introduction and the discussion of an article were 5 
considered too subjective and require subject-specific expert knowledge, and so had not been 6 
included in the data extraction form that was already used in the PRE-study. Similarly, the seven 7 
items 3, 4, 5, 8, 11, 17 and 18 referring to the methods and the results of an article were excluded 8 
because their evaluation essentially requires profound expert knowledge with respect to the medical 9 
background and methodology. For more details, see S5 Doc. 10 
 11 
  12 
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4 Reporting 1 
This study assesses the reporting quality of published TMP-studies. For such a ‘research on research’-2 
project, no specific reporting guideline is available. The current project, however, shows some 3 
features (observational kind, literature search) that allow us to use different reporting statements as 4 
guidance. Specifically, we used the STROBE guideline for general aspects of the project and the 5 
PRISMA statement for aspects around literature search [43, 44].  6 
 7 
  8 
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Results 1 
 2 
1 Selected journals and assessed articles 3 
Overall 4 
The POST-study was planned to use the same journals as much as was feasible, but some changes to 5 
journals was required for practical reasons (Table 2). All journals are of higher impact (impact factor 6 
2012 >4). Three journals (BCRT, BJC, JCO) belong to the group of journals that have published 7 
REMARK. These three journals and CCR explicitly ask authors submitting a manuscript for adherence 8 
to REMARK (Table 2). 9 
 10 
Table 2: Cancer journals included in the PRE-study and in the POST-study 11 
Journal 
(alphabetical 
order) 
PRE-study POST-study Impact 
factor† 
2012 
Publication 
of REMARK 
Author instructed 
to adhere to 
REMARK 
 N assessed 
articles 
 N assessed 
articles* 
02/2009‡ 08/2014 
BCRT - -  10/10 4.5 YES [38] YES [42] YES 
BJC - -  10/10 5.1 YES [33] UNK YES 
Canc  10  6/6 5.2 NO NO NO 
CaRes  10 - -§ 8.6 NO NO NO 
CCR  10  10/10 7.8 NO YES YES 
IJC  10  7/7 6.2 NO NO NO 
JCO  10  10/10 18.0 YES [35] YES YES 
* N citing group/n not-citing group; † source: InCitesTM Journal Citation Reports; ‡ check was done within the PRE-study; §journal was 12 
excluded because only one eligible article citing REMARK was identified; UNK=unknown 13 
  14 
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The sample included 53 articles in both the citing group and the not-citing group (total 1 
n=106). Similarly to the PRE-study, the distribution of cancer sites was diverse. As a consequence of 2 
the additional inclusion of BCRT, however, the proportion of breast and/or ovarian cancer studies 3 
was higher in the current sample (PRE-study: 30%, POST-study: 44%). Articles in the not-citing and 4 
citing groups were well matched by journal, year and issue (S1 Table). 5 
 6 
Citing group 7 
At least one of the REMARK publications was referenced in all the articles assigned to the citing 8 
group.  Since REMARK is a methodological tool, its citation is expected to be given in the methods 9 
section of the article, with a statement like “The study is reported in accordance to the REMARK 10 
guideline”. Although REMARK was indeed cited most often in the methods section (n=39, 74%), some 11 
citations appeared in other sections of the manuscripts. The statements in which REMARK was cited 12 
varied greatly. While some authors correctly referred to the reporting of the study, other authors 13 
referred to REMARK in relation to the design, the conduct and the analysis of the study. For example, 14 
the statement “This analysis was conducted according to the reporting recommendations for tumor 15 
marker guidelines for prognostic studies …” was provided by the authors in the methods section [45]. 16 
Other statements are difficult to understand, such as “Protein expression was evaluated using a 17 
semiquantitative weighted histoscore method by two observers as previously described … in 18 
accordance with the Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) 19 
guidelines …” [46]. 20 
Three manuscripts were accompanied by a completed REMARK checklist [47-49]; two of 21 
these had overlapping authorship [47, 48]. For unknown reasons, none of these lists cover the full 22 
REMARK checklist of 20 items. Moreover, some explanations were difficult to assess, for example 23 
regarding the item ‘Flow of patients’, the authors stated “This is not a staged analysis. The evaluated 24 
cohort is described …” [48]. 25 
 26 
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2 Comparison of reporting quality 1 
Not-citing group (POST-study) versus PRE-study 2 
Overall, there was a slight but not relevant improvement in the mean overall score: PRE-study 53.4% 3 
(range: 10%-90%), not-citing group of POST-study 57.7% (range: 20%-100%, Wilcoxon rank sum test: 4 
p = 0.33, Fig 2). This small difference, however, vanished when we included only articles published in 5 
the four journals assessed in both periods: PRE-study 56.5% (range: 10%-80%, n=40), not-citing group 6 
of POST-study 56.4% (range: 20%-80%, n=33). Some items showed an improvement in reporting from 7 
the past to the present, while others showed a decline (S2 Table). An improvement, for example, was 8 
visible for item 2 ‘Patient characteristics’ (PAT): PRE-study 54%, POST-study 72%. In this case, the 9 
improvement was also visible for the single assigned elements like the element ‘Selection of patients’ 10 
(PAT1) showing improvement from 64% in the PRE-study to 77% in the not-citing group (Fig 3A). In 11 
contrast, a remarkable decline from past to present was seen for item 9 ‘Rationale for sample size’ 12 
(SIZ; Fig 3B, S5 Doc). Overall, there remains much room for improvement of reporting. 13 
 14 
Fig 2: Percentages of articles adequately reporting information for 10 selected items of the 15 
REMARK checklist.  16 
The items are sorted by percentages obtained in the PRE-study [30]. See Table 1 or S2 Table for 17 
explanation of abbreviations used for different checklist items. 18 
 19 
Fig 3: Percentages of articles adequately reporting information for two checklist items and their 20 
single elements respectively assigned.  21 
(A) Checklist item 2 ‘Patient characteristics’ (PAT), (B) checklist item 9 ‘Rationale for sample size’ 22 
(SIZ). See S2 Table for explanation of abbreviations used for different elements of data extraction and 23 
checklist items. 24 
  25 
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Citing group versus not-citing group (POST-study) 1 
When comparing the not-citing group and the citing group, there was essentially no difference in 2 
mean scores: not-citing group 57.7% (range: 20%-100%), citing group 58.1% (range: 30%-100%, Fig 3 
2). Again, some single checklist items showed an improvement in reporting from the past to the 4 
present, while others showed a decline. Most pronounced, item 7 ‘Clinical endpoints’ (END)  was 5 
reported better in the citing group than in the non-citing group (40% vs 66%, respectively; S2 Table), 6 
whereas it was the other way around for item 13 ‘Distribution of demographic characteristics’ (DEM; 7 
55% vs 42%). Fig 3 similarly illustrates observed percentages for item 2 (PAT) and item 9 (SIZ). 8 
 9 
Additional analysis 10 
Because we observed some unexpected statements by authors citing REMARK which could imply a 11 
lack of understanding of REMARK as a reporting guideline, an additional comparison was made of 12 
articles grouped by journals requesting (4 journals, 80 articles) or not requesting (2 journals, 26 13 
articles) adherence to REMARK, irrespective whether authors cited or not cited REMARK (Table 2). 14 
On average, the overall score for articles published in journals requesting adherence to REMARK was 15 
higher (59.9%) than for the other group (51.9%). This ordering was also present for each single 16 
checklist item. 17 
 18 
  19 
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Discussion 1 
Several years after REMARK was introduced, and with many published discussions of the reporting 2 
quality in health research and prominence given to the role of poor reporting in contributing to 3 
research waste, some improvement of the reporting quality of TMP-studies was expected [30, 50, 4 
51]. However, our assessment of articles from the post-REMARK period did not reveal any relevant 5 
improvement over the quality of articles assessed in the earlier study [30]. The overall reporting 6 
quality is still very poor. Authors still frequently fail to report important aspects of their study such as 7 
the source of the study population, fully defined clinical endpoints, and an explanation of the sample 8 
size. 9 
Moreover, we observed essentially no difference in reporting quality when comparing 10 
articles citing and not citing REMARK. Because citing REMARK means the author of the respective 11 
article is aware of the guideline, one would expect to see superior reporting quality compared to 12 
articles not citing REMARK.  Our findings, however, raise the question of whether the main scope of 13 
REMARK is really understood. To overcome any misunderstanding the REMARK group already 14 
published a manuscript that elaborates and explains each item of the REMARK checklist in detail [40, 15 
41]. However, authors of articles assessed in this project (published ≤2012) could not have known 16 
this amendment because it was published in 2012. 17 
Because of these disappointing results we decided to conduct an additional unplanned 18 
comparison between reporting qualities of articles published in journals requesting or not requesting 19 
adherence to REMARK in the submission guidelines. This revealed somewhat better reporting in the 20 
group of articles published in journals requesting adherence to REMARK.  21 
 22 
  23 
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1 Limitations of study 1 
To allow a fair comparison of results between past and current assessments, the current project was 2 
designed to be as similar as possible to the previous study. Also, the current team largely overlaps 3 
with the team of the past study. Furthermore, all the documents including the data extraction form 4 
could be utilized. A pilot study was conducted to ensure comparability between data extractions in 5 
the past and current projects. Still, some systematic differences between the two surveys cannot be 6 
ruled out. In addition although judged as sufficient to address the methodological research question, 7 
the number of studies assessed was relatively small in both the pre-study and the current study. 8 
 One obvious limitation of this study is that we could not identify enough articles in all 9 
journals considered in the first study, so two new journals (BCRT, BJC) were included. Since both 10 
additional journals published REMARK and requesting adherence to it, the overall result might be 11 
biased. For this reason, an additional analysis was conducted by restricting articles to those published 12 
in the four journals Canc, CCR, IJC and JCO that were considered in both assessments. As result, the 13 
small improvement observed in the overall sample vanished. Overall we found no improvement in 14 
reporting quality of prognostic factor studies in the first (about six) years since REMARK was 15 
published.  Repeating the investigation with papers published after more than ten years (say in 2016) 16 
may provide better results.   17 
 Another issue relates to the overall score used to evaluate quality of reporting. The overall 18 
score included summation of sufficiently reported REMARK items, often based on several elements 19 
of the data extraction form. For transparency, a description of the overall score and detailed results 20 
are provided in the supporting information (S5 Doc, S2 Table). 21 
 22 
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2 Our findings in the context of published literature 1 
To our knowledge, there is just one other published study assessing quality of TMP-studies, which 2 
reviews studies of prognostic markers for colorectal cancer published in 2009-11, a slightly earlier  3 
period to the current project [52]. The authors assessed adherence to the complete REMARK 4 
checklist and found a mean score of 60 out of 78, but still emphasize deficiencies in reporting similar 5 
to those seen in our study across all cancers.  6 
 Concern about reporting quality applies across all areas of health research. To overcome this 7 
problem reporting guidelines for many different study designs and research areas are available [32]. 8 
Similarly to our project, other study groups also assessed the question of whether reporting quality 9 
improved over time. For randomized controlled trials and in relation to the CONSORT statement, 10 
modest improvement in reporting quality was reported but reporting was still considered suboptimal 11 
[53, 54]. For other guidelines like STARD or STROBE, some slight improvements were also reported 12 
[55-58]. The current study on REMARK is essentially in line with those other reported results.  13 
Da Costa et al systematically examined reasons for citing STROBE guideline [43, 59]. Similar 14 
to our observations, the authors reported that the guideline is often used inappropriately. These 15 
observations raise doubts on the general understanding of reporting guidelines and their aim, as 16 
already discussed in 2008 [60].        17 
 Evidence of a relation between reporting quality and endorsement of reporting guidelines by 18 
journals is limited [54, 61]. Our data suggest that a request of adherence by the journal might be 19 
useful. In order to provide conclusive evidence, well-planned prospective studies in cooperation with 20 
editors are needed to explore and enhance journal editor led interventions to improve reporting 21 
[61].  22 
Based on our experience in the current project, we became aware that expert knowledge of 23 
the research subject and methods is often required to evaluate details needed for good reporting. 24 
Editors and reviewers may find it hard to recruit and focus experts on reporting as well as results of 25 
research studies. For authors writing a manuscript, access to sufficient expertise should be easier 26 
18 
 
because the research team should include experts relevant to the clinical and methodological aspects 1 
of a study. On the other hand, reporting guidelines are misunderstood by many authors [62], and 2 
further initiatives like the E&E paper for REMARK may be very helpful [40, 41].   3 
 4 
3 Quality of medical research in general 5 
In general, the quality of medical research, including other aspects besides reporting, has been 6 
criticized heavily in the last years [1, 14, 19, 31, 63-66].  To overcome these issues, several important 7 
contributions as well as the introduction of reporting guidelines have been seen recently. For 8 
example, the PROGnosis RESearch Strategy (PROGRESS) group published a series of articles to 9 
provide a framework on different aspects in prognostic research [11, 67-70]. Also, the STRATOS 10 
(STRengthening Analytical Thinking for Observational Studies) initiative was founded recently that 11 
aims to derive guidance documents related to design and analysis of observational studies [71, 72].  12 
Overall, the need for transparency in medical research still appears to lack widespread 13 
acceptance and research endeavour [21, 23, 73]. Researchers remain insufficiently aware of the need 14 
to make their research clear and understandable to other researchers, as well as practising 15 
physicians, patients and other stakeholders (e.g. pharmaceutical companies, funding agencies). 16 
Particularly in medical research it is important that studies can be repeated by other research groups, 17 
requiring transparency through good reporting of research methods and results. 18 
Registration of all studies and data sharing [1, 23, 73-76] have been recommended to 19 
improve knowledge of ongoing and past research. In this context, good reporting is a main 20 
prerequisite. Even a well-conducted and well-analysed study that is poorly reported can be 21 
considered as waste of resources.  22 
 23 
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Conclusions  1 
Tumour marker prognostic studies are still very poorly reported. To improve the situation the 2 
REMARK recommendations need to be followed, which will require combined efforts of authors, 3 
editors, reviewers and methodologists. An extensive guidance document is available to facilitate the 4 
understanding of REMARK. However, this study is another example illustrating that publication of 5 
guidelines is insufficient and that more pressure on authors, reviewers and editors is needed to 6 
improve on this unfortunate situation. We support the proposal of one reviewer of this manuscript 7 
that an electronic checklist (a web-based form of the checklist on which the authors can indicate 8 
where in the manuscript information for an item is addressed) can be a valuable instrument of the 9 
submission process. Ideally, such an electronic document can also provide further information about 10 
the reporting items. We hope that more journals will be willing to request such checklists in their 11 
submission process. Good reporting is not just nice to have. It is essential for any research to be 12 
useful but also for the limitations of research to be understood. Good reporting is also essential for 13 
systematic reviews that bring together and overview research studies to achieve a high level of 14 
evidence.   15 
20 
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Dear Reviewer, 
 
Thank you very much for reviewing our manuscript. Subsequently, you will find our reply following 
each of your comments. 
 
Kind regards, 
Peggy Sekula 
 
 
 
 
Reviewers' comments: 
 
Reviewer #1: Well done study, nicely presented; I only have a few comments: 
 
 
1. is there a reason for the precise time limit that you placed to review the 
journals you did. 
 
Reply: The PRE-study includes publications published mainly in 2006 and few in 2007. The POST-
study includes publications published mainly in 2011 and 2012 but in single situations (Journals: 
Canc, IJC) it goes back to 2007. We ensured that there is no overlap in selected manuscripts. The 
search itself was conducted in March 2013 - therefore the defined period of assessed articles of 
2007 to 2012. We did not repeat the search as we already had enough publications but also due to 
limited manpower. No change in the manuscript. 
 
  
2. I understand that you chose the journals that represent those in the first 
survey, but would there be value in surveying other journals with high impact 
factor in the field (JNCI, JAMA Oncol, Lancet Oncol) in addition to those 
already chosen? For example, the latter two didn't exist when the first 
survey was done. however, this may be a new study for a subsequent article. 
 
Reply: The project focused on the assessment of the potential improvement in reporting quality. For 
this reason, we attempted to select articles from the same journals in order to sensibly compare 
results with the past. Since we did not identify enough articles in the preferred journals we already 
included 2 other journals knowing that this limits our conclusions regarding comparability of results. 
Of course, we could have included other journals as well. In this situation, however, the focus would 
be rather on quality assessment in general and between journals. Currently we can only 
hypothesize that reporting quality will be similarly poor in other related journals. Additionally, due to 
limited manpower in this project, such assessment could be only addressed in a new study. Parts of 
these explanations were already mentioned in the first version (see p.6 Material and Methods 2nd 
paragraph und p. 16 Discussion: 1 Limitations of study). No change in the manuscript.  
 
 
  
Response to Reviewers
3. It would be a great service if the REMARK authors would prepare an 
automated, electronic checklist for authors that includes each of the points 
and provides appropriate questions as to whether that point is covered or 
not. Perhaps such a project could be brought up in the Discussion? 
  
Reply: Thank you for your suggestion of an ‘automated, electronic checklist’. It is an excellent idea 
as it may provide extra help in the future, in addition to the free downloads available for current 
REMARK checklist and extensive guidance already published. We are therefore more than willing to 
include your suggestion in the conclusions of our manuscript (p. 19).  However, we consider it more 
as the task and the privilege of the authors of the REMARK checklist (two of us (DGA and WS) 
belong to them). It will be discussed in this group and it is likely that an electronic checklist on the 
web providing explanations to each item in pop up windows will be available soon. However, it is 
unclear if journals are willing to add such an instrument to their submission guidelines. Anyhow, it is 
worth a try.  
